Summary & Overview
CPT 81535: Tumor Cell Culture with DAPI Staining and Drug Response Algorithm
CPT code 81535 represents a laboratory diagnostic assay that cultures tumor cells from female reproductive tissues, assesses cell morphology and DAPI staining, and uses a predictive algorithm to produce a drug response score for a single agent or combination. This code reflects an advanced, tissue-based functional assay used in oncology to inform therapeutic selection and personalize treatment strategies. Nationally, such assays are increasingly relevant as precision oncology and targeted therapies expand.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for 81535, how the service is typically delivered in laboratory settings, and what to expect from payer coverage perspectives. The publication summarizes benchmark considerations for utilization and reimbursement, highlights relevant policy and coding updates where applicable, and explains clinical implications for oncology care teams and laboratory services.
The report is intended for a national audience of payers, laboratory directors, oncology clinicians, and coding professionals seeking concise, actionable information on the clinical nature of the assay, common sites of service, and the areas of payer focus for coverage and coding. Data not available in the input will be noted where applicable.
Billing Code Overview
CPT code 81535 describes a laboratory procedure in which a lab analyst cultures tumor cells obtained from female reproductive organs or tissues, evaluates cell morphology and DAPI (4’,6-diamidino-2-phenylindole) staining, and applies a predictive algorithm to generate a drug response score for a single drug or a drug combination. This service is a laboratory-based predictive assay that combines cell culture, fluorescence staining, microscopy assessment, and computational analysis to inform potential therapeutic response.
-
Service type: Laboratory diagnostic assay involving tumor cell culture, microscopy-based staining (DAPI), morphologic assessment, and predictive algorithm analysis to derive drug response scores.
-
Typical site of service: Clinical or commercial pathology laboratories, molecular diagnostics laboratories, or specialized oncology reference labs where cultured tumor cell assays and algorithmic analyses are performed.
Clinical & Coding Specifications
Clinical Context
A typical patient is a woman diagnosed with a gynecologic malignancy (for example, ovarian, endometrial, or cervical cancer) who requires functional drug-response testing to guide systemic therapy selection. Tumor tissue or ascites-derived tumor cells are obtained during surgery or image-guided biopsy and sent to the laboratory. In the lab, a trained technologist cultures tumor cells, assesses cell morphology and DAPI nuclear staining to verify tumor cell content and viability, and runs a validated predictive algorithm to generate a drug response score for a single chemotherapeutic agent or a specified drug combination. The clinical workflow includes specimen collection in the operating room or interventional radiology suite, transport under chain-of-custody to the molecular or cellular oncology lab, cell culture and staining (technical component), algorithmic analysis, and generation of a report used by the treating gynecologic oncologist or medical oncologist to inform systemic therapy planning. Typical sites of service are a hospital outpatient laboratory or an independent clinical diagnostic laboratory with capabilities for cell culture and specialized image-based assays.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the physician or professional interpretation component if split billing applies (lab technical/ professional split). |